TSC-101

May 06, 2026 — TScan Therapeutics, Inc. (Nasdaq: TCRX) reported Q1 2026 financial results (three months ended March 31, 2026) and provided pipeline updates focused on its TCR-engineered T cell (TCR‑T) programs. The company expects early clinical data in Q2 2026 from Cohort C (>10 patients treated using a “commercial-ready” manufacturing process) of the ALLOHA™ Phase 1 heme trial evaluating lead candidate TSC‑101 to prevent relapse after allogeneic hematopoietic cell transplantation. TScan plans to initiate a Phase 3 pivotal study of TSC‑101 (ALLOHA‑2™) in AML/MDS patients in Q2 2026, and to start a Phase 1 trial of CD45-targeted candidates TSC‑102‑A01 and TSC‑102‑A03 (HLA A01:01 and A03:01) in 2H 2026; an ASGCT 2026 poster will present preclinical details on these CD45 TCRs.

Financials: revenue $1.0M (vs $2.2M Q1 2025; attributed to Amgen collaboration timing); R&D $21.9M (vs $29.8M); G&A $8.2M (vs $8.6M); net loss $28.7M (vs $34.1M). Cash and cash equivalents were $128.1M (plus $5.0M restricted cash), projected to fund operations into 2H 2027.